PRN: 'In Vitro Diagnostic Revenues Will Reach $59.2bn in 2015' Says visiongain Report

15/giu/2011 10.04.28 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

'In Vitro Diagnostic Revenues Will Reach $59.2bn in 2015' Says visiongain Report

 
[15-June-2011]
 

LONDON, June 15, 2011 /PRNewswire/ --


A new report by London-based business information company visiongain predicts that world in vitro diagnostic revenues will reach $59.2bnin 2015. That market generated $44.6bn in 2010, according to In Vitro Diagnostics: World Market Outlook 2011-2021, published in June 2011.

In vitro diagnostics (IVD) is increasing in importance with the drive towards personalised medicine. The main reasons for the predicted growth in IVD revenues are widening applications for IVD tests and greater access to healthcare in countries such as China and India. In particular, the genetic testing submarket will show high revenue growth, visiongain's market analysis shows.

Antibody-based products and DNA test kits will remain important, the report notes. The diagnostics industry will benefit from advances in cytogenetic techniques using molecular imaging. Those methods include optical imaging and magnetic resonance imaging (MRI). Development of scanning probe microscope (SPM) systems will improve fluorescence in situ hybridization (FISH) techniques. The technological advances will help to detect and characterise cancers and other diseases.

Dr Gordon Low, healthcare reports editor, said: "The world IVD market will benefit from the entry of new products, services and companies this decade. There will be great possibilities for better targeted medicine through in vitro diagnostic technologies. Patients will benefit from diagnostic companies' progress."

Visiongain forecasts that the overall in vitro diagnostics market will grow steadily to 2021. Patients, healthcare providers, drug developers and diagnostics companies will benefit. The future of the IVD industry and market appears promising through developing technologies and increasing demand from many areas of healthcare, the published report concludes. This new study complements visiongain's wide range of analytical reports in healthcare and other industry areas.  


Table of Contents

1. Executive Summary
1.1 Overview of the In Vitro Diagnostics World Market, 2011-2021
1.2 The Scope of this Report
1.3 Chapter Outlines
1.4 Research and Analysis Methods

2. Introduction to the In Vitro Diagnostics Industry
2.1 What are In Vitro Diagnostic (IVD) Tests?
2.2 Classifying IVD: EDMA Classification
2.2.1 Clinical Chemistry
2.2.2 Immunochemistry
2.2.3 Haematology
2.2.4 Microbiology
2.2.5 Genetic Testing
2.3 Classifying IVD: Disease Areas
2.4 Regulatory Issues in the IVD Market
2.4.1 FDA Classifications
2.4.2 Regulation of IVD Tests
2.5 Types of IVD Tests
2.6 Personalised Medicine: Pharmacogenomics, Pharmacogenetics, Theranostics and Proteomics
2.6.1 Pharmacogenomics
2.6.2 Proteonomics
2.7 Sensitivity and Specificity

3. The Global In Vitro Diagnostics Market, 2011-2021
3.1 The Global IVD Market in 2009
3.2 Global IVD Market Forecast, 2011-2021
3.3 Global IVD Market Forecasts by EDMA Category, 2011-2021
3.3.1 Clinical Chemistry Market Forecast, 2011-2021
3.3.2 Immunochemistry Market Forecast, 2011-2021
3.3.3 Haematology Market Forecast, 2011-2021
3.3.4 Microbiology (Culture) Market Forecast, 2011-2021
3.3.5 Immunotechnology for Infectious Diseases Market Forecast, 2011-2021
3.3.6 Genetic Testing Market Forecast, 2011-2021
3.3.7 Cytogenetic Tests: FISH (Fluorescence In-Situ Hybridisation)
3.3.7.1 What is FISH?
3.3.7.2 Cytogenetics and FISH Will Drive Growth in the Genetic Testing Market
3.4 Point-of-Care Testing Market Forecast, 2011-2021
3.5 Laboratory Testing Market Forecast, 2011-2021

4. In Vitro Diagnostics: Leading National Markets, 2011-2021
4.1 Leading National Markets for IVD Tests in 2010
4.2 The US IVD Market: Forecast and Outlook, 2011-2021
4.3 The Japanese IVD Market: Forecast and Outlook, 2011-2021
4.4 Leading European IVD Markets: Forecasts and Outlook, 2011-2021
4.4.1 The German IVD Market, 2011-2021
4.4.2 The French IVD Market, 2011-2021
4.4.3 The Italian IVD Market, 2011-2021
4.4.4 The Spanish IVD Market, 2011-2021
4.4.5 The UK IVD Market, 2011-2021
4.5 Top 5 EU Markets, 2011-2021
4.6 Chinese IVD Market: Forecast and Outlook, 2011-2021
4.7 Indian IVD Market: Forecast and Outlook, 2011-2021
4.8 IVD Revenues from Leading Emerging Markets, 2011-2021
4.9 Revenues in the Rest of the World, 2011-2021
4.10 Global IVD Market by Region, 2010

5. Important Therapy Areas for IVD Tests
5.1 Diabetes
5.2 Oncology
5.3 Infectious Disease
5.3.1 Hospital-Acquired Infections
5.3.2 HIV
5.3.3 Tuberculosis
5.3.3.1 Skin Tests
5.3.3.2 Smear Microscopy
5.3.3.3 Microbiological Culture
5.3.3.4 Nucleic Acid Based Testing
5.3.3.5 Immunoassays
5.3.3.6 Phage Assay
5.4 Influenza
5.5 Reproductive Tests
5.6 Drug Abuse
5.6.1 Drugs Commonly Tested For
5.6.2 Types of Samples
5.7 Cardiovascular Disease
5.7.1 Cardiac Markers
5.7.2 Cholesterol Screening

6. Leading Companies in the IVD Industry and Market
6.1 Top 5 IVD Manufacturers
6.2 Roche
6.3 Siemens AG
6.4 Abbott Laboratories
6.5 Beckman Coulter
6.6 Becton Dickinson
6.7 Laboratory Services
6.7.1 Quest Diagnostics
6.7.2 Laboratory Corporation of America
6.7.3 Direct-to-Consumer Genomic Testing Companies

7. Theranostics and Personalised Medicine, 2011-2021
7.1 What is Personalised Medicine?
7.2 Maximising Benefits to Healthcare Stakeholders
7.3 Minimising Harm
7.4 Increasing Compliance
7.5 Streamlining Clinical Trials
7.6 Reviving Failed or Withdrawn Drugs
7.7 Reducing the Costs of Healthcare
7.8 Shifting from Reaction to Prevention
7.9 What is Required for Personalised Medicine to Become Widespread?
7.9.1 The Cost of Genomic Sequencing Must Fall
7.9.2 Large Scale Studies and Databases
7.9.3 A Healthcare IT Infrastructure that Integrates Clinical Data and Other Research
7.9.4 Medical Education
7.9.5 Guaranteed Reimbursements
7.10 Theranostics Forecast, 2011-2021

8. Drivers and Restraints in the IVD Industry and Market, 2011-2021
8.1 SWOT Analysis of the IVD Market Area
8.2 Factors Driving Growth of the IVD Market
8.3 Factors Restraining Growth of the IVD Market

9. Opinions from Our Industry Survey
9.1 Godwin Liu, Marketing Manager, Shenzhen Mindray Bio-Medical Electronics Co.
9.1.1 About Mindray
9.1.2 Unmet Needs in the IVD Market
9.1.3 Growth in the IVD Sector
9.1.4 Challenges Faced by the IVD Market
9.1.5 Market Expansion for IVD Products
9.2 Interview 2: Director of a Diagnostics Company
9.2.1 Most-Promising Therapeutic Areas for IVD
9.2.2 Unmet Medical Needs in IVD
9.2.3 Greatest Obstacles to Market Growth
9.2.4 Prospects for IVD Market Growth in Developing Countries
9.2.5 Prospects for Theranostics

10. Conclusions
10.1 In Vitro Diagnostics are Vital to Clinical Decision Making
10.2 Significant Growth of In Vitro Diagnostics Market from 2010 to 2021
10.3 The Top Five Manufacturers Command the Majority of the IVD Market
10.4 Expansion of the World Market Boosted by Rising Revenues in the Developing Healthcare Markets
10.5 IVD Solutions are the Cornerstone of Personalised Medicine
10.6 Concluding Thoughts on this Expanding Industry and Market

For further information about this report please click on http://www.visiongain.com/Report/629/In-Vitro-Diagnostics-World-Market-Outlook-2011-2021  

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Pharmaceutical, Telecoms, Energy, Defence and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 


Contact: Sara Peerun
Tel: +44(0)207-336-6100
Email: sara.peerun@visiongainglobal.com
Web: http://www.visiongain.com


blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl